Pharmacokinetics of irbesartan are not altered in special populations

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 1, 2002, Pages 112-122

  Marino, Maria R ^a   Vachharajani, Nimish N ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin II receptor antagonists; Children; Hepatic impairment; Irbesartan; Pharmacokinetics; Renal impairment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; PRIORITY JOURNAL; SIDE EFFECT; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; FEMALE; KIDNEY DISEASE; LIVER DISEASE; MALE; MIDDLE AGED; REVIEW;

ADOLESCENT; ADULT; AGED; BIPHENYL COMPOUNDS; CHILD; COMPARATIVE STUDY; FEMALE; HEART FAILURE, CONGESTIVE; HUMAN; HYPERTENSION; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGE; TETRAZOLES; HUMANS; MIDDLE AGED;

EID: 0035985499     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200207000-00014     Document Type: Article

References (47)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Press
2. Evidence-based health policy: Lessons from the Global Burden of Disease study
3. Blood pressure, stroke, and coronary heart disease: Part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
4. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats
5. Efficacy and safety of losartan
6. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
7. Tissue angiotensin II system in the human heart
8. 1 sub-type angiotensin II receptor antagonist
9. A review of the new angiotensin II receptor antagonist irbesartan
10. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues
11. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects
12. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
13. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
14. Pharmacology of irbesartan
15. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations
16. Pharmacokinetics and pharmacodynamics of irbesartan in patients with mild to moderate hypertension
17. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
18. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
19. The effects of the angiotensin II receptor antagonist irbesartan in patients with congestive heart failure
20. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats
21. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
22. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure
23. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial. Losartan Heart Failure Survival Study ELITE II
24. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure
25. Irbesartan compared with lisinopril in patients with mild to moderate heart failure
26. Drug-patient interactions and their relevance in the treatment of heart failure
27. Clinical pharmacokinetics in heart failure: An updated review
28. Angiotensin II receptor antagonists: Potential in elderly patients with cardiovascular disease
29. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
30. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
31. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure
32. The effect of age on the pharmacokinetics of irbesartan
33. The effects of age and gender on the pharmacokinetics of irbesartan
34. The pharmacokinetics of irbesartan in hypertensive children and adolescents
35. Effect of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
36. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan
37. Microalbuminuria in essential hypertension and diabetes mellitus
38. Diabetic retinopathy
39. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection
40. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
41. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
42. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure
43. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
44. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program (SHEP)
45. Medical Research Council trial of treatment of hypertension in older adults: Principal results
46. Trials of antihypertensive therapies in children
47. Safety of irbesartan in the treatment of mild to moderate systemic hypertension